The Journal of Pathology · 2002 · 39 citations · 19 references
MedicineOncologyUrologyGenitourinary OncologyMolecular OncologyNeoplasiaBenign Prostatic HyperplasiaEpigenetic BiomarkersProstate BiopsyProstate CancerProstate PathologyTumor MarkersBiomarkersBiopsy Of Prostate LesionsGlutathione S-transferase ActivityMethylation-specific AmplificationNeoplastic DiseasePromoter HypermethylationProstatic AdenocarcinomaProstatic Biomarkers
Epigenetic DNA alterations such as promoter hypermethylation of glutathione S-transferase P1 (GSTP1) in prostatic adenocarcinoma frequently constitute tumour biomarkers. Neoplastic transformation was identified in washings of prostate biopsies by GSTP1 promoter hypermethylation, using methylation-specific PCR (MSP). Twenty-six patients undergoing sextant transrectal prostate biopsies for clinically suspected prostate cancer were enrolled. All ten patients diagnosed with adenocarcinoma (100%) and four of six patients with prostatic intraepithelial neoplasia (67%), but none of ten patients with benign hyperplasia (0%), exhibited GSTP1 promoter hypermethylation in at least one out of six biopsy washings. Since this approach is transferable to various cancer entities, a sensitive and specific DNA-based analysis of biopsy material seems generally feasible without impeding routine histopathological examination.
19
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
J Costello, Michael C. Frühwald, Dominic J. Smiraglia et al. · Nature Genetics · 2000 · 1.4K citations
Steven A. Belinsky, Kristen J. Nikula, William A. Palmisano et al. · Proceedings of the National Academy of Sciences · 1998 · 962 citations · Full text
W H Lee, Ronald A. Morton, Jonathan I. Epstein et al. · Proceedings of the National Academy of Sciences · 1994 · 843 citations
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
William A. Palmisano, Kevin K. Divine, Geno Saccomanno et al. · PubMed · 2000 · 817 citations